Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Fe...
Chinese Government Supports High-level Reform and Increased Access to Developmen...
LEXICON ANNOUNCES FDA APPROVAL OF INPEFA™ (SOTAGLIFLOZIN) FOR TREATMENT OF HEART...
Dual Inhibition of SGLT1 and SGLT2 with Sotagliflozin Released Progress on AMERI...
News Express | The Latest Analysis of Double SGLT InhibitorsPhase lll Trial Rele...
lntestinal SGLT1 as a therapeutic target in COVID-19-relateddiabetes: A "two-edg...
Sotagliflozin, a SGLT1/SGLT2 dual inhibitor submitted listingapplication to FDA ...
2021 ADA Update Guide: Type l Diabetes Prevention Medicine— "Teplizumab" Debut
The Reform Plan For The Evaluation System For Clinicians WasReleased